GLP1R and heart failure: Improvements in heart failure outcomes with GLP-1 receptor agonists have thus far been demonstrated only with specific agents such as subcutaneous semaglutide [25], the first in class dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonist tirzepatide [26], as well as the nonsteroidal mineralocorticoid receptor antagonist finerenone [27].